Pay in 4 interest-free payments of $7.28 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
MOTS-c is typically administered via subcutaneous injection into the abdomen, lateral thigh, or flank, rotating injection sites to prevent tissue accumulation
Why it matters: Inadequate protein accelerates muscle loss, slows metabolism, and undermines the long-term success of your weight loss
Both compounds slow gastric emptying
That slowdown can be uncomfortable, leading to constipation
Reported Vision Changes During GLP-1 Therapy Clinical trials for semaglutide and tirzepatide report blurry vision in fewer than 3% of participants, making it a rare but documented occurrence
After 68 weeks, average weight loss in the retatrutide 12 mg group was a remarkable 28.7%, equating to an average weight loss of 71 lbs
